Alastair Garfield - 11 Feb 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role: Chief Scientific Officer
Signature: /s/ Stephen Vander Stoep, attorney-in-fact for Alastair Garfield
Issuer symbol: RYTM
Transactions as of: 11 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 13 Feb 2026, 17:47:38 UTC
Previous filing: 03 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Garfield Alastair	Chief Scientific Officer	222 BERKELEY STREET, 12TH FLOOR, BOSTON	/s/ Stephen Vander Stoep, attorney-in-fact for Alastair Garfield	13 Feb 2026	0002027261

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RYTM	Restricted Stock Units	Award	$0	+16,650		$0.000000	16,650	11 Feb 2026	Common Stock	16,650		Direct	F1, F2
transaction	RYTM	Stock Options (Right to Buy)	Award	$0	+25,000		$0.000000	25,000	11 Feb 2026	Common Stock	25,000	$98.47	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2	The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.
F3	The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.